Fidaxomicin versus oral vancomycin for <i>Clostridioides difficile</i> infection among patients at high risk for recurrence based on real-world experience
Outcomes were similar between patients treated with FDX and VAN for the treatment of CDI among those at high risk for rCDI, using our outlined criteria. Although we observed a trend toward lower rates of rCDI among immunocompromised patients, this finding was not significant. Further investigation is needed to determine which patients with CDI may benefit from FDX.
Authors
- Natasha N. Pettit
- Cynthia T. Nguyen (ORCID: https://orcid.org/0000-0001-8530-6890)
- Alison Lew (ORCID: https://orcid.org/0000-0002-7993-1814)
- Christopher Lehmann (ORCID: https://orcid.org/0000-0002-1111-2169)
- Elizabeth Bell (ORCID: https://orcid.org/0000-0002-6070-075X)
- Jennifer Pisano (ORCID: https://orcid.org/0000-0002-8156-3731)
Institutions
- University of Chicago (US)
Publication Details
- Journal
- Infection Control and Hospital Epidemiology
- Published
- 2024-10-04
- DOI
- https://doi.org/10.1017/ice.2024.145
- Citations
- 2
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.78